المصدر: Zacks Investment Research
وكالة أنباء
الأسهم
أهمية متوسطة
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.
الرموز ذات الصلة
1
H
HALO
HALO
المصدر: Zacks Investment Research
زيارة المصدر